Intellia Therapeutics
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered...
Latest News
4 days ago · seekingalpha.com
Intellia Therapeutics, Inc. (NTLA) Discusses Lonvo-z Clinical Data and Commercial Launch Preparations in HAE TranscriptIntellia Therapeutics, Inc. ( NTLA ) Discusses Lonvo-z Clinical Data and Commercial Launch Preparations in HAE November 12, 2026 10:00 AM EST Company Participants Jason Fredette - Vice President of Investor Relations & Corporate Communications John Leonard - President, CEO & Director Jing Marantz - EVP & Chief Medical Officer Maria Natale - Senior Vice President of Commercial Fred Cohen Conference Call Participants Marc Riedl Danny Cohn Joseph Thome - TD Cowen, Research Division Jonathan Miller - Evercore ISI Institutional Equities, Research Division Silvan Tuerkcan - Citizens JMP Securities, LLC, Research Division Alec Stranahan - BofA Securities, Research Division Maurice Raycroft - Jefferies LLC, Research Division Lut Ming Cheng - JPMorgan Chase & Co, Research Division Jeffrey Stith - Wells Fargo Securities, LLC, Research Division John Boyle - William Blair & Company L.L.C., Research Division Binita Shah Andy Chen - Wolfe Research, LLC Jasmine Fels - Barclays Bank PLC, Research Division Lydia Erdman Debanjana Chatterjee - JonesTrading Institutional Services, LLC, Research Division Jade Montgomery Presentation Operator Good morning, everyone, and welcome to the Intellia Therapeutics HAE Investor Event.
4 days ago · globenewswire.com
Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran (lonvo-z) at ACAAI 2026CAMBRIDGE, Mass., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced highlights from its seven presentations at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting in Phoenix, Arizona. Intellia will host an investor webcast today at 10:00 a.m. ET to review certain data from the ACAAI presentations, share perspectives from key opinion leaders and discuss the company's preparations for a planned commercial launch of lonvo-z in HAE.
10 days ago · seekingalpha.com
Intellia: Quiet Q3 Earnings As All Eyes Turn To March 2027 Approval DecisionIntellia Therapeutics approaches a pivotal FDA decision in March 2027 for lonvo-z, potentially the first in vivo CRISPR therapy for hereditary angioedema. Lonvo-z's Phase 3 data showed ~87% attack reduction and a clean safety profile, positioning NTLA as a transformative one-time treatment in a crowded, high-cost market. Commercial success hinges on payer acceptance, physician adoption, and pricing strategy, with initial revenues likely modest but long-term potential significant if approved.
11 days ago · zacks.com
Intellia's Q3 Loss Wider Than Expected, Stock Down, Pipeline in FocusNTLA's Q3 loss deepens, while progress on its lonvo-z & nex-z clinical programs & a $400 million loan facility strengthen its pipeline & financial flexibility.
12 days ago · zacks.com
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Lags Revenue EstimatesIntellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.91 per share versus the Zacks Consensus Estimate of a loss of $0.82. This compares to a loss of $0.92 per share a year ago.
12 days ago · globenewswire.com
Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business UpdatesOn track to complete lonvo-z commercial readiness efforts in advance of March 10, 2027 PDUFA date New lonvo-z patient perspectives and Phase 1/2 durability data to be included in investor webcast and multiple presentations next week at ACAAI 2026 Completed enrollment in MAGNITUDE-2 Phase 3 clinical trial in ATTRv-PN; advanced enrollment in MAGNITUDE in ATTR-CM Existing cash resources expected to fund operations at least into 2028 and well beyond lonvo-z's anticipated commercial launch, with recent term loan facility providing additional financial flexibility CAMBRIDGE, Mass., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial results for the third quarter ended September 30, 2026.
13 days ago · globenewswire.com
Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran (Nex-z) for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy (ATTRv-PN)CAMBRIDGE, Mass., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the completion of enrollment in MAGNITUDE-2, the Phase 3 clinical trial of nex-z in patients with ATTRv-PN.
14 days ago · globenewswire.com
Intellia Therapeutics Announces Upcoming Nexiguran Ziclumeran (nex-z) Medical Congress PresentationsPresentation at AHA on Nov. 9 to highlight cardiac outcomes following a single dose of nex-z in patients with ATTRv-PN with mixed phenotype from the Phase 1 clinical trial Presentation at ISA on Nov. 18 to include up to four years of follow-up data in patients with ATTRv-PN CAMBRIDGE, Mass., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced it will present new clinical data at two medical meetings in November.
19 days ago · globenewswire.com
Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran (Lonvo-z) Investor Event and Seven Presentations at ACAAI 2026CAMBRIDGE, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced two oral presentations and five poster presentations at the American College of Allergy, Asthma & Immunology (ACAAI) 2026 Annual Scientific Meeting, taking place November 12-16 in Phoenix, Arizona. Intellia also announced that it will host an investor webcast on Thursday, November 12, at 8 a.m. MT / 10 a.m. ET to share highlights from the presentations, provide perspectives from HAE key opinion leaders and discuss the company's preparations for a planned commercial launch of lonvo-z in HAE.
1 month ago · globenewswire.com
Intellia Therapeutics Appoints Jing L. Marantz, M.D.CAMBRIDGE, Mass., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the appointment of Jing L. Marantz, M.D., Ph.D., as Executive Vice President and Chief Medical Officer, effective October 26, 2026. Dr. Marantz is an accomplished drug development leader with more than 25 years of experience in the biopharmaceutical industry that includes the successful advancement of several now-approved rare disease therapies. In this role, Dr. Marantz will lead the company's translational, development, regulatory and medical affairs functions.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove NTLA